Adrian Rawcliffe Sells 14,362 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock

Adaptimmune Therapeutics plc (NASDAQ:ADAP) CEO Adrian Rawcliffe sold 14,362 shares of Adaptimmune Therapeutics stock in a transaction dated Tuesday, January 11th. The stock was sold at an average price of $3.56, for a total value of $51,128.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Adrian Rawcliffe also recently made the following trade(s):

  • On Tuesday, January 4th, Adrian Rawcliffe sold 5,532 shares of Adaptimmune Therapeutics stock. The stock was sold at an average price of $4.06, for a total value of $22,459.92.

Shares of Adaptimmune Therapeutics stock opened at $3.30 on Friday. Adaptimmune Therapeutics plc has a 52-week low of $3.16 and a 52-week high of $7.34. The stock has a 50-day simple moving average of $3.98 and a 200-day simple moving average of $4.45.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings results on Thursday, November 4th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.04). The firm had revenue of $1.20 million for the quarter, compared to analyst estimates of $1.20 million. Adaptimmune Therapeutics had a negative net margin of 2,499.92% and a negative return on equity of 53.31%. During the same quarter in the prior year, the firm earned ($0.23) earnings per share. Equities analysts expect that Adaptimmune Therapeutics plc will post -0.69 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. PFM Health Sciences LP lifted its holdings in shares of Adaptimmune Therapeutics by 45.0% during the 2nd quarter. PFM Health Sciences LP now owns 3,627,900 shares of the biotechnology company’s stock valued at $15,455,000 after buying an additional 1,126,597 shares during the last quarter. Baillie Gifford & Co. lifted its holdings in shares of Adaptimmune Therapeutics by 9.6% during the 3rd quarter. Baillie Gifford & Co. now owns 12,824,980 shares of the biotechnology company’s stock valued at $66,306,000 after buying an additional 1,128,061 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Adaptimmune Therapeutics during the 2nd quarter valued at about $546,000. Vigilare Wealth Management lifted its holdings in shares of Adaptimmune Therapeutics by 84.2% during the 3rd quarter. Vigilare Wealth Management now owns 99,950 shares of the biotechnology company’s stock valued at $517,000 after buying an additional 45,700 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its holdings in shares of Adaptimmune Therapeutics by 5,908.6% during the 3rd quarter. Daiwa Securities Group Inc. now owns 15,382 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 15,126 shares during the last quarter. Institutional investors and hedge funds own 71.38% of the company’s stock.

A number of research firms recently issued reports on ADAP. Zacks Investment Research lowered Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 10th. SVB Leerink reissued a “hold” rating and issued a $7.00 price target on shares of Adaptimmune Therapeutics in a research note on Tuesday, November 9th. Finally, Wells Fargo & Company lifted their target price on Adaptimmune Therapeutics from $6.00 to $7.00 and gave the company an “equal weight” rating in a research note on Wednesday, September 22nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $7.75.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Recommended Story: Limitations of the P/E Growth ratio

Insider Buying and Selling by Quarter for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.